Grant: Operating Grant - PA: IMHA New investigators - Bridge Funding
McGill University
$100,000.00
Prevention and treatment of hip fractures with cholinesterase inhibitors
FY 2012-13
Summary
Two drugs frequently used to treat Alzheimer disease (AD), donepezil and rivastigmine, are known to stimulate a group of neurons in the brain that play a major role in maintaining memory. While these drugs have been widely used in the treatment of AD and other forms of dementia since the mid-1990s, their potential effect on bone biology had not been explored.
Recent research indicated that certain neurons can regulate bone metabolism and that their damage results in weaker bones. But little was known about the potential that increased activity by these neurons might have on bone. In a recent study Dr Tamimi team determined that the use of donepezil and rivastigmine, two drugs that in theory could increase the activity of bone-regulating neurons, is associated with a beneficial effect on bone strength and a decreased risk of hip fracture in Alzheimer's patients. Accordingly, Dr Tamimi and Dr Nicolau propose to further investigate the potential use of these drugs for prevention and treatment of bone fractures in osteoporosis patients.
Department
Program
Operating Grant - PA: IMHA New investigators - Bridge Funding
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
274978
Name
Tamimi Faleh
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Public, Community & Population Health 2
Projecttitle
Prevention and treatment of hip fractures with cholinesterase inhibitors
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: IMHA New investigators - Bridge Funding
Keyworddelim
Alzheimer; Cholinesterase Inhibitors; Cohort; Cox Hazards; Donepezil; Hip Fracture; Logistic Regression; Nested Case-Control; Relative Risk; Rivastigmine
Abstract
Two drugs frequently used to treat Alzheimer disease (AD), donepezil and rivastigmine, are known to stimulate a group of neurons in the brain that play a major role in maintaining memory. While these drugs have been widely used in the treatment of AD and other forms of dementia since the mid-1990s, their potential effect on bone biology had not been explored.
Recent research indicated that certain neurons can regulate bone metabolism and that their damage results in weaker bones. But little was known about the potential that increased activity by these neurons might have on bone. In a recent study Dr Tamimi team determined that the use of donepezil and rivastigmine, two drugs that in theory could increase the activity of bone-regulating neurons, is associated with a beneficial effect on bone strength and a decreased risk of hip fracture in Alzheimer's patients. Accordingly, Dr Tamimi and Dr Nicolau propose to further investigate the potential use of these drugs for prevention and treatment of bone fractures in osteoporosis patients.
Competitiondate
201209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tamimi, Faleh
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~